siRNA沉默t-bet基因对CD4、CD8T淋巴细胞亚群IFN-γ产生的影响

利用化学合成针对人t-bet基因的小干扰RNA（siRNA）,转染体外培养的人外周血单个核细胞,利用流式细胞仪分选纯化CD4^＋、CD8^＋T淋巴细胞,半定量RT-PCR检测CD4^＋、CD8^＋T淋巴细胞中t-betmRNA的表达变化,流式细胞术检测转染前后IFN-γ产生的变化情况。探讨转录因子t-bet对人CD4^＋、CD8^＋T淋巴细胞亚群IFN-γ产生的调控作用。与对照组相比,转染后的人CD4^＋、CD8^＋T淋巴细胞t-betmRNA表达水平明显下降;转染siRNA后,CD4＋T淋巴细胞中IFN-γ＋细胞比例为（18.46±6.86）%,与对照组（50.20±5.91）%比较有显著性差异（P〈0.01）;CD8＋T淋巴细胞IFN-γ＋细胞比例为（74.18±9.33）%,和对照组（76.51±6.49）%比较差异不明显（P〉0.05）。体外转录合成的siRNA可有效降低人CD4^＋、CD8^＋T淋巴细胞t-bet的基因表达;转录因子t-bet对人不同淋巴细胞亚群IFN-γ的产生所起作用不同。     

人肿瘤浸润淋巴细胞的克隆化

肿瘤组织经机械剪切和酶消化分离肿瘤浸润淋巴细胞(TIL)。TIL在含1000U/ml重组人白细胞介素-2(rhIL-2)的培养液中培养6d后,植入含1000U/ml rhIL-2的软琼脂半固体培养基中培养,7d后将形成的克隆转移到含rhIL-2的培养液中培养。~(51)Cr释放法测定结果表明,约30％的克隆对NK敏感的K562细胞和对NK不敏感的H7402肝癌细胞有细胞毒性,为具有杀瘤活性的TIL杀伤克隆(TIL-K)。60％以上TIL-K克隆在含IL-2的培养液中可持续地增殖2～3个月,其细胞数可扩增至10~8～10~9,并始终保持对肿瘤细胞的细胞毒性。TIL-K克隆的表型为CD3~ 、CD4~-、CD8~ 、CD16~-,有T细胞抗原受体β链基因的表达,说明其属T细胞系统。采用半固体-液体两步培养法可获取大量高纯度具有广谱杀瘤活性的TIL,本研究有助于TIL的深入研究和临床应用。     

肝癌细胞Fas-FasL途径反击免疫细胞

为了探讨肝癌细胞反击肿瘤浸润淋巴细胞(TIL)的机制,在体外进行肝癌细胞和TIL混合培养后,检测两种细胞FasL、Fas、caspase-8基因的表达情况,以及肿瘤细胞反击时TIL凋亡比例的变化.将肝癌细胞与TIL按照不同的比例共培养后,流式细胞术检测TIL凋亡率;实时荧光定量PCR检测肝癌细胞与TIL FasL、Fas和caspase-8基因的表达情况;以及Western印迹检测FasL、caspase-8的表达情况.不同浓度的肝癌细胞与TIL共同培养48 h后,随着肝癌细胞接种浓度的增加,TIL凋亡率明显增加(P＜0.01).与正常人肝细胞相比,人肝癌细胞FasL mRNA表达含量明显增高(P＜0.01).与人肝癌细胞共同培养24 h后,TIL Fas、caspase-8基因mRNA的表达也明显升高;TIL caspase-8的表达也明显升高.结果表明,肝癌细胞可以通过Fas系统诱导TIL发生凋亡,这为肝癌的免疫逃逸和肿瘤反击机制提供了依据.     

双歧杆菌脂磷壁酸对化疗荷瘤小鼠免疫功能的影响

目的探讨双歧杆菌脂磷壁酸对5-氟尿嘧啶（5-FU）化疗肝癌H22荷瘤小鼠免疫的影响及其作用机制。方法双歧杆菌脂磷壁酸处理5-Fu化疗的H纶荷瘤Balb／c小鼠,MTT法检测NK细胞和CTL细胞杀伤活性;采用流式细胞仪检测荷瘤小鼠脾细胞中T亚群比例;用RT-PCR和Western Not方法分别检测荷瘤小鼠肿瘤组织Foxp3和TIM-3mRNA及蛋白的表达变化。结果荷瘤小鼠脾细胞中CD4^＋ CD25^＋Tmg比例高,并存在Foxp3和TIM-3 mRNA及蛋白的高表达,经双歧杆菌LTA和5．Fu处理后CD4^＋CD25^＋Tmg比例下降,Foxp3和TIM-3mRNA及蛋白表达水平也均呈下调趋势,但5-FU单独处理后的荷瘤小鼠脾细胞中CD4^＋细胞比例也减少,NK细胞和CTL杀伤率均降低,而双歧杆菌LTA处理后CD4^＋细胞比例,NK细胞和CTL杀伤率却明显增加。二者联合处理也能增加CD^＋细胞比例及NK细胞和CTL杀伤率。结论双歧杆菌脂磷壁酸联合5-FU可通过增强NK细胞和CTL杀伤能力,同时抑制TIM-3／TIM-3L途径,降低CD4^＋CD25^＋Tmg的免疫抑制活性,增强机体细胞免疫来提高化疗抗肿瘤效果,减轻化疗副作用,增强宿主对化疗的耐受性,从而提高抗肿瘤作用。     

建立适用于旋毛虫抗肿瘤相关基因筛选的动物模型

目的为利用抑制消减杂交（SSH）法筛选旋毛虫抗肿瘤相关基因,建立理想的动物模型获取可靠的实验样本。方法Balb／c小鼠随机分为检测组（Tester）和驱动组（Driver）,Tester为经口服感染旋毛虫250条、400条和550条组,Driver为不接种组,在感染后11d,两组同时在皮下分别接种SP^2/0细胞2×10^6个,只,检测组和驱动组小鼠荷瘤后,于20d后处死,采集两组肿瘤组织和脾脏组织,用天平称量肿瘤块的重量,游标卡尺测量肿瘤块3个互相垂直直径进行体积比较;为了检测两组小鼠免疫情况,又采用流式细胞术检测体内T淋巴细胞的动态变化,以便评估所需样本的可靠性。结果将肿瘤组织与正常组织分离后,经统计分析比较两组肿瘤块重量和体积大小的差异均极为显著（P〈0．01）通过检测T淋巴细胞亚类,FACS共检测1×10^5个细胞,分别得到脾细胞中CD3^＋、CD4^＋和CD8^＋T淋巴细胞的数量,感染组小鼠机体的CD3^＋、CD4^＋、CD8^＋和CD4^＋／CD8^＋显著增高,在接种不同剂量的旋毛虫后荷瘤,小鼠脾脏特异的T淋巴细胞亚类：CD3^＋差异显著（P〈0．05）;CD4^＋差异显著（P〈0．05）;CD8^＋差异显著（P〈0．05）;CD4^＋／CD8^＋差异显著（P〈0．05）。通过以上指标的测定,我们认为所建立的动物模符合SSH的实验要求。结论建立的旋毛虫抗实体瘤动物模型,可用于旋毛虫抗肿瘤差异基因筛选的实验起始材料,为进一步研究旋毛虫抗肿瘤分子机制创造条件。     

肿瘤浸润性γδT细胞（γδTIL）CDR3δ1区的序列分析

目的对肿瘤浸润性γδT细胞（γδTIL）CDR3δ1区进行序列分析。方法用固相包被抗体,体外扩增14例肿瘤组织（胃癌、肾癌、卵巢癌、膀胱癌、食管癌、肺癌、嗜铬细胞瘤）和2例肿瘤腹水（浆乳癌）的γδ肿瘤浸润淋巴细胞（tumor infiltration lymphocytes,γδTIL）,RT-PCR法扩增CDR3δ1基因片段,测序分析其序列特征。结果 16例γδTIL的CDR3δ1确实存在优势序列,不完全相同。其中4例胃癌来源的γδTIL中3例的CDR3δ1优势序列相同,3例食管癌来源的γδTIL中2例的CDR3δ1优势序列相同。结论体外扩增培养的γδTIL的TCR CDR3δ1序列具有相对优势特征。不同个体的同种组织来源的γδTIL的CDR3δ1优势序列趋于相同。     

多发性骨髓瘤患者外周血淋巴细胞亚群分析及与预后因子的相关性

目的通过对多发性骨髓瘤（MM）患者外周血淋巴细胞亚群的检测以评价MM患者机体的免疫功能状态。方法采用流式细胞术检测36例MM患者和25例健康志愿者外周血T、B淋巴细胞、NK细胞及CD4＋CD25＋T细胞的表达。结果与正常对照组相比,MM患者外周血的CD4、CD19细胞的表达显著下调,CD8细胞的表达显著上调,CD4/CD8比值则显著降低（P〈0.05或〈0.01）;MM患者外周血的CD4＋CD25＋T细胞占CD3＋T细胞的比例明显增高（P〈0.01）,且与血清中的β2-MG浓度成正相关（γ=0.56,P〈0.05）。结论 MM患者体内存在淋巴细胞亚群的异常表达、CD4＋CD25＋Treg细胞的异常扩增,可能是MM患者体内广泛存在免疫缺陷的一个主要原因。     

冻存密度对外周血单个核细胞冻存效果的影响

探讨冻存密度对外周血单个核细胞(Peripheral blood mononuclear cell,PBMC)冻存效果的影响。设定新鲜PBMC组(F组)及3个PBMC冻存密度组即2.0×10~7/mL(A组),4.0×10~7/mL(B组),6.0×10~7/mL(C组)。通过对冻存前后的PBMC活率及复苏后多种细胞因子诱导的杀伤细胞(Cytokine-induced killer,CIK)的扩增倍数、淋巴细胞亚群、体外杀伤效率进行比较,验证其冻存效果。结果显示,冻存前F组与冻存后A组、B组、C组的细胞活率分别为(96.0±0.3)%、(95.6±0.4)%、(94.7±0.2)%和(94.9±0.4)%,B组与C组显著低于A组,P0.05;细胞扩增14 d后,F组与A组、B组、C组细胞扩增倍数分别为(156.4±18.2)倍、(160.2±28.4)倍、(126.1±19.8)倍和(110.4±11.3)倍,B组与C组显著低于F组(P0.05);PBMC冻存前复苏后淋巴细胞亚群结果无显著差异。与F组相比,A组、B组、C组细胞扩增14 d后,CD3+、CD3+CD4+、CD3+CD8+、CD3-CD56+、CD3+CD56+淋巴细胞亚群无显著差异(P0.05),体外杀伤效率无显著差异(P0.05)。过高的冻存密度会影响PBMC冻存效果而间接影响细胞的复苏应用,而过低的冻存密度则增加冻存体积而大大提高冻存成本,因此,选择合适的细胞冻存密度是细胞库或细胞银行必须要考虑的问题。     

北京地区实验恒河猴外周血T淋巴细胞亚群分析

目的测定正常实验恒河猴外周血T淋巴细胞亚群,获取基础数值。方法使用BD FACS Calibur流式细胞仪,Cell QuestTM3.3分析软件,应用CD3-Percp、CD4-FITC、CD8-PE荧光标记的抗体,对北京地区84只实验恒河猴的外周血T淋巴细胞亚群进行统计分析。结果北京地区实验恒河猴外周血CD3＋,CD4＋T淋巴细胞占淋巴细胞（LYM）的百分比为32.82%±5.93%;CD3^＋CD8^＋T淋巴细胞占淋巴细胞百分比为（23.99±6.34）%;CD4^＋/CD8^＋的比值为1.45±0.41;LYM百分比为白细胞的（49.70±14.00）%;LYMF为（4.634±2.181）×106/mL。结论实验用恒河猴T淋巴细胞亚群的基础数值测定为相关比较医学研究奠定基础。     

流式细胞仪分选人外周血T淋巴细胞的方法建立与评价

目的:利用流式细胞仪同时分离外人周血单个核细胞中T淋巴细胞并检测其分离纯度及存活率。方法:本文采用流式细胞仪同时分选人外周血CD4~+、CD8~+T淋巴细胞为例,推而广之,采用人外周血淋巴细胞分离液梯度离心法制备外周血单个核细胞,采用流式细胞仪同时分选CD4~+、CD8~+T淋巴细胞,分离细胞再通过流式细胞仪回测其分离纯度并通过台盼蓝染色检测分离细胞的存活率。结果:采用此方法能有效人外周血细胞CD4~+、CD8~+T淋巴细胞,分选前CD4~+淋巴细胞纯度为(50.5±11.5)%、CD8~+T淋巴细胞纯度为纯度为(15.4±7.1)%;分选后CD4~+T淋巴细胞纯度为(94.3±1.3)%、CD8~+T淋巴细胞纯度为(93.6±1.6)%;分选后CD4~+T淋巴细胞存活率为(95.3±1.8)%,CD8~+T淋巴细胞存活率为(94.8±1.5)%,细胞的形态完整。结论:采用人外周血淋巴细胞分离液梯度离心法制备外周血单个核细胞后利用流式细胞仪分选的方法能够高效、快速的分离人外周血CD4~+、CD8~+T淋巴细胞,且存活率高,为进一步研究其功能提供了保证。采用不同的荧光抗体标记其他淋巴细胞亚群,也能高效、快速的分离出细胞。     

体外制备和增殖烟曲霉特异性T细胞的研究

目的体外制备和增殖烟曲霉特异性T淋巴细胞。方法从健康志愿者外周抗凝血中分离并体外扩增DC,利用加热灭活的烟曲霉孢子作为抗原,体外共孵育制备烟曲霉孢子负载的DC,进一步将此成熟DC与源自同一个体的去除了DC细胞的外周血细胞共培养,体外诱导并扩增烟曲霉特异性T淋巴细胞。应用ELISPOT(酶联免疫斑点)技术检测活化T细胞IFN-γ的分泌情况,流式细胞仪检测细胞因子胞内合成情况,并分析功能细胞的类型和比例。结果 ELISPOT分析显示:PBMC+DC+Conidia实验组IFN-γ分泌(87.33±1.33/4.0×105)高于其他对照组,具有统计学意义(P0.05)。细胞因子流式细胞仪分析显示:PBMC+DC+Conidia组中,2.76%的细胞分泌IFN-γ,其中1.61%为CD4+T细胞,与各对照组相比具有统计学意义(P0.05)。获得的烟曲霉特异性T细胞可以在体外可进行大量增殖。结论本文结果显示烟曲霉孢子在体外可以作为变应原诱导产生烟曲霉特异性CD4+T细胞介导的Th1型免疫反应,为未来制备和扩增烟曲霉特异性T细胞及过继免疫治疗侵袭性曲霉病提供实验基础。     

Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies

To study the CD4+ and CD8+ tumor infiltrating lymphocytes (TIL) in the antitumor response, we propagated these subsets directly from tumor tissues with anti-CD3:anti-CD8 (CD3,8) and anti-CD3:anti-CD4 (CD3,4) bispecific mAb (BSMAB). CD3,8 BSMAB cause selective cytolysis of CD8+ lymphocytes by bridging the CD8 molecules of target lymphocytes to the CD3 molecular complex of cytolytic T lymphocytes with concurrent activation and proliferation of residual CD3+CD4+ T lymphocytes. Similarly, CD3,4 BSMAB cause selective lysis of CD4+ lymphocytes whereas concurrently activating the residual CD3+CD8+ T cells. Small tumor fragments from four malignant melanoma and three renal cell carcinoma patients were cultured in medium containing CD3,8 + IL-2, CD3,4 + IL-2, or IL-2 alone. CD3,8 led to selective propagation of the CD4+ TIL whereas CD3,4 led to selective propagation of the CD8+ TIL from each of the tumors. The phenotypes of the TIL subset cultures were generally stable when assayed over a 1 to 3 months period and after further expansion with anti-CD3 mAb or lectins. Specific 51Cr release of labeled target cells that were bridged to the CD3 molecular complexes of TIL suggested that both CD4+ and CD8+ TIL cultures have the capacity of mediating cytolysis via their Ti/CD3 TCR complexes. In addition, both CD4+ and CD8+ TIL cultures from most patients caused substantial (greater than 20%) lysis of the NK-sensitive K562 cell line. The majority of CD4+ but not CD8+ TIL cultures also produced substantial lysis of the NK-resistant Daudi cell line. Lysis of the autologous tumor by the TIL subsets was assessed in two patients with malignant melanoma. The CD8+ TIL from one tumor demonstrated cytotoxic activity against the autologous tumor but negligible lysis of allogeneic melanoma targets. In conclusion, immunocompetent CD4+ and CD8+ TIL subsets can be isolated and expanded directly from small tumor fragments of malignant melanoma and renal cell carcinoma using BSMAB. The resultant TIL subsets can be further expanded for detailed studies or for adoptive immunotherapy.     

Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumour cells does not affect tumour-specificity

The therapeutic potential of adoptive therapy using tumour-infiltrating lymphocytes (TIL) has been demonstrated in a number of clinical trials. However, freshly isolated tumour-infiltrating lymphocytes (TIL) are often impaired in their proliferative and cytotoxic responses, which limits their use in immunotherapy. Several hypotheses with regard to the poor effector function of TIL have been postulated, including the production of immunosuppressive factors by tumour cells. In a previous paper we reported the efficient expansion of immunoreactive TIL from a variety of solid tumours by stimulation with a combination of monoclonal antibodies (mAbs) against CD3 and CD28. In the present study we analysed whether this protocol would be improved by the removal of tumour cells at the start of the culture. We tested a highly immunogenic tumour, melanoma, and a poorly immunogenic tumour, colon carcinoma. Removal of tumour cells highly improved anti-CD3/CD28 stimulated expansion of TIL from colon carcinoma, resulting in a significantly higher percentage of potentially tumour-specific CD8-positive T-cells and a reduced CD4/CD8 ratio compared to expansion in the presence of tumour cells. In contrast, expansion and CD4/CD8 ratio of melanoma-derived TIL was not significantly influenced by the removal of autologous tumour cells. CD3/CD28-stimulated melanoma TIL cultured in the absence of tumour cells showed specific lysis of autologous tumour cells comparable to melanoma TIL cultured in high-dose IL2. However, no cytotoxicity could be detected in colon TIL irrespective of the culture conditions used. On the other hand, 3/8 colon carcinoma TIL cultures and 9/12 melanoma-derived TIL cultures showed IFN secretion upon stimulation with autologous tumour cells. We conclude that stimulation of TIL with a combination of mAbs to CD3 and CD28 in the absence of tumour cells induces efficient expansion of potentially tumour-specific cells from a highly and a poorly immunogenic tumour. Removal of tumour cells does not have a negative influence on the generation of tumour-specific T cells, while cell yield improves. Therefore, for large-scale cultures this protocol can efficiently induce the outgrowth of tumour-specific TIL, at the same time providing a useful source of autologous tumour cells that can be stored and used to direct or test antitumour specificity.     

Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2

In order to expand tumor-infiltrating lymphocytes (TIL) efficiently and in order to use them for immunotherapy, we utilized lipopolysaccharide-activated B cells (LPS blasts) as costimulatory-signal-providing cells in an in vitro culture system. TIL, prepared from subcutaneously inoculated B16 melanoma, failed to expand when cultured with anti-CD3 monoclonal antibody (mAb) alone followed by a low dose of interleukin(IL)-2. In contrast, such TIL did expand efficiently in culture with both anti-CD3 mAb and LPS blasts followed by culture with IL-2. These findings suggest that the presence of LPS blasts in the initial culture was essential for the cell expansion. The expansion of TIL was partially blocked by the addition of CTLA4 Ig, which is an inhibitor of costimulatory molecules such as CD80 and CD86, and was almost blocked by the addition of anti-(Fc receptor γII)mAb. These findings thus indicate that such molecules, in conjunction with the receptor on the LPS blasts, participate in the efficient expansion of TIL. The B16-derived TIL, which expanded in our culture system, were predominantly CD8+T cells and showed a higher level of cytolytic activity against B16 melanoma than either lymphokine-activated killer cells or TIL cultured with a high dose of IL-2. In addition, the in vitro expanded B16-derived TIL produced interferon γ, but not IL-4, in response to B16 melanoma. What is more important, the adoptive transfer of such TIL had a significant antitumor effect against pulmonary metastasis in B16 melanoma, even without the concurrent administration of IL-2. Collectively, our results thus indicate the therapeutic efficacy of the protocol presented here for antitumor immunotherapy with TIL.     

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

Adoptive cell transfer (ACT) of in vitro expanded autologous tumor-infiltrating lymphocytes (TIL) has been shown to exert therapeutic efficacy in melanoma patients. We aimed to develop an ACT protocol based on tumor-specific T cells isolated from peripheral blood and in vitro expanded by Dynabeads? ClinExVivo?CD3/CD28. We show here that the addition of an in vitro restimulation step with relevant peptides prior to bead expansion dramatically increased the proportion of tumor-specific T cells in PBMC-cultures. Importantly, peptide-pulsed dendritic cells (DCs) as well as allogeneic tumor lysate-pulsed DCs from the DC vaccine preparation could be used with comparable efficiency to peptides for in vitro restimulation, to increase the tumor-specific T-cell response. Furthermore, we tested the use of different ratios and different types of Dynabeads? CD3/CD28 and CD3/CD28/CD137 T-cell expander, for optimized expansion of tumor-specific T cells. A ratio of 1:3 of Dynabeads? CD3/CD28 T-cell expander to T cells resulted in the maximum number of tumor-specific T cells. The addition of CD137 did not improve functionality or fold expansion. Both T-cell expansion systems could generate tumor-specific T cells that were both cytotoxic and effective cytokine producers upon antigen recognition. Dynabeads?-expanded T-cell cultures shows phenotypical characteristics of memory T cells with potential to migrate and expand in vivo. In addition, they possess longer telomeres compared to TIL cultures. Taken together, we demonstrate that in vitro restimulation of tumor-specific T cells prior to bead expansion is necessary to achieve high numbers of tumor-specific T cells. This is effective and easily applicable in combination with DC vaccination, by use of vaccine-generated DCs, either pulsed with peptide or tumor-lysate.     

Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas

Introduction Vγ9Vδ2 T lymphocytes are reported to participate in the anti-tumor immune surveillance in human. They are known to recognize phosphoantigens and molecules expressed on cells undergoing neoplasic transformation. In this study, we investigated phenotype and anti-tumor cytotoxicity of ex vivo expanded Vγ9Vδ2 T cells in view of adoptive immunotherapy. Materials and Methods Experiments were performed with peripheral blood samples from eleven patients [six colorectal carcinoma (CRC), four hepatocellular carcinoma (HCC), one sarcoma] and sixteen healthy donors. Results/Discussion Ex vivo expansion of Vγ9Vδ2 T cells could be achieved by a single dose of phosphoantigen, either bromohydrin pyrophosphate or zoledronate, and supported by exogenous IL-2. After 2 weeks, expanded Vγ9Vδ2 T lymphocytes acquired the effector memory phenotype CD45RA⁻CD45RO^highCD27⁻. They expressed NKG2D and CD161 and the proinflammatory CXCR3 and CCR5 chemokine receptors. Vγ9Vδ2 T cells displayed a strong lytic activity toward a broad panel of tumor cell lines or primary cultures. Interestingly, HCC and CRC primary cells could be lysed by autologous Vγ9Vδ2 T cells whereas autologous normal cells were not sensitive to the lysis. mAbs blocking assays demonstrated that TCR was the most important receptor involved in the lysis of tumor cells. However, NKG2D receptor could deliver a costimulatory signal enhancing the lysis of HCC and CRC tumors expressing MICA/B. Treatment of tumor cells by the mevalonate pathway inhibitor, zoledronate, enhanced the killing of both HCC and CRC. Expansion index of Vγ9Vδ2 T cells was in similar levels in healthy donors or in cancer patients and total expansion was suitable for adoptive immunotherapy. Conclusion These results provide a rationale for the clinical evaluation of Vγ9Vδ2 T lymphocytes in HCC and CRC.     

生殖器疱疹初发患者外周血淋巴细胞检测结果分析

目的检测生殖器疱疹初发患者（GH）外周血T淋巴细胞亚群、NK细胞和B细胞的表达水平，探讨其发病机制与细胞免疫功能之间的关系。方法应用流式细胞仪检测20例初发生殖器疱疹患者外周血T淋巴细胞亚群、NK细胞和B细胞的表达水平，并与60例复发性生殖器疱疹患者（RGH）、35例健康对照者外周血检测结果相比较。结果（1）初发组和对照组相比，除NK细胞降低差异有显著性外，其他差异无显著性；（2）初发组与复发组相比，初发组T细胞、CD4^＋细胞、CD4^＋／CD8^＋均高于复发组，CD8^＋细胞百分比低于后者，差异有显著性；B细胞、NK细胞比例差异无显著性；（3）复发组与对照组相比，外周血中T细胞、CD4^＋细胞、NK细胞所占比例，CD4^＋／CD8^＋均降低，差异有显著性；CD8^＋细胞百分比升高，差异有显著性；B细胞比例差异无显著性。结论生殖器疱疹初发患者存在细胞免疫功能异常。     

磁感应热疗联合放疗对小鼠4T1移植瘤的杀伤作用

目的:探讨磁感应热疗联合放疗在小鼠4T1乳腺癌细胞株皮下移植瘤模型中的治疗作用.方法:小鼠经皮下移植4T1乳腺癌细胞株,建立皮下移植瘤模型,待肿瘤直径达到10mm左右,然后将其分为以下4组进行处理:标准对照组(未做任何特殊处理,C组)、单纯热疗组(48±2℃10min,MIH组)、单纯放疗组(10Gyx2次,R组)、热放联合组(10Gyx1次+48±2℃10min,MIH+R组).观察各治疗组和对照组的肿瘤体积的大小、肿瘤体积抑制率.每组分别在实验处理后24小时处死小鼠应用免疫组化检测肿瘤组织中Bcl-2和Caspase-3的表达情况.结果:热疗后的第1-4周MIH+R组的肿瘤体积抑制率分别为(64.38±17.97)％、(73.90± 9.48)％、(77.43±0.71)％、(73.17±8.58)％;MIH组的分别为(40.66+ 21.46)％、(54.60±10.20)％、(51.22+ 5.05)％、(39.53±5.49)％;R组的肿瘤体积抑制率分别为(51.60±18.93)％、(57.53±9.76)％、(52.34±7.42)％、(35.42±4.14)％.与对照组相比,各治疗组均能抑制肿瘤的生长(P＜0.05).其中以MIH+R组抑瘤作用最显著.与其它组相比,Bcl-2在MIH+R组的表达显著下降,而Caspase-3的表达显著上升,差异具有显著性(P＜0.05).结论:磁感应热疗与放疗均能诱导肿瘤细胞凋亡,有效地抑制小鼠4T1乳腺癌细胞株皮下移植瘤的生长,而磁感应热疗与放疗的联合治疗的抑瘤作用最显著,而且降低了放疗剂量.